جستجوی استاد راهنمای دانشگاهی

Sampsa Hautaniemi is a Professor at the Department of Biochemistry and Developmental Biology within the Faculty of Medicine at the University of Helsinki. He serves as Principal Investigator of the Systems Biology of Drug Resistance in Cancer research group and holds docentship in the Faculty of Medicine. Professor Hautaniemi actively supervises doctoral students across multiple programs including the Doctoral Programme in Biomedicine, Doctoral Programme in Clinical Research, and Doctoral Programme in Integrative Life Science. His research focuses on systems biology approaches to understand drug resistance mechanisms in cancer, particularly ovarian cancer. His work integrates computational biology, genomics, epigenetics, and bioinformatics to develop precision medicine approaches for cancer treatment. His laboratory develops innovative computational methods and experimental models including patient-derived organoids to study tumor evolution, identify therapeutic targets, and predict treatment responses. Analysis of his recent publications reveals a strong emphasis on understanding tumor heterogeneity, clonal evolution during therapy, and the development of computational tools for cancer genomics. His work spans multiple disciplines including cancer biology, computational biology, immunology, and precision medicine, with a particular focus on high-grade serous ovarian cancer as a model system. Scientific Awards: The Anders Jahre Medical Prize to young medical scientists (2014) for outstanding research on systems biology and cancer The Finnish Medical Foundation 50-years jubileum award (2010) Professor Hautaniemi has supervised numerous doctoral students and early-career researchers, contributing significantly to cancer research education. His research is supported by multiple active projects including the DECIDER project (Clinical Decision via Integrating Multiple Data Levels to Overcome Chemotherapy Resistance in High-Grade Serous Ovarian Cancer) funded until 2026, as well as projects from the Academy of Finland, Cancer Foundation, and industry partners like Orion Corporation. His laboratory maintains a patient-derived organoid biobank for high-grade serous ovarian cancer and develops computational tools like Jellyfish for visualizing tumor evolution.

• Systems Biology
• Cancer Research
• Drug Resistance
• +۷ مورد دیگر

Dr. Phyllis I. Hanson is the Minor J. Coon Professor and Chair of Biological Chemistry at the University of Michigan Medical School. She also holds secondary appointments in Neurology and Cell and Developmental Biology, with affiliations to the Rogel Cancer Center and Precision Health Initiative. Research Interests: Her lab investigates mechanisms of cellular membrane stress sensing and repair, focusing on lysosomes and the ESCRT pathway. Her work integrates biochemical, cell biological, and advanced imaging techniques to study organelle membrane dynamics in health and disease. Recent Publications highlight her contributions to understanding ESCRT function in endolysosomal trafficking, membrane resilience under osmotic stress, and protein degradation pathways. These studies intersect with neurodegeneration, cancer biology, and infectious disease. Scientific Awards: AAAS Fellow Keck Scholar Searle Scholar Sloan Scholar McKnight Scholar Grants from NIH and disease-focused foundations since 2018 support her work on ESCRT pathway analysis, HSC70 AMPylation, and signal relay during cell migration. Leadership: She co-chairs Michigan Medicine’s Endowment for the Basic Sciences and chaired the 2024 Gordon Research Conference on Lysosomes & Endocytosis. She serves as Associate Editor of the Journal of Biological Chemistry .

• Membrane Biology
• Cellular Stress Response
• Lysosomal Function
• +۲ مورد دیگر

Lucy Glover is a Researcher and Group Leader of the Trypanosome Molecular Biology laboratory at the Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France. She joined the institute in March 2016 as a G5 group leader, focusing on the molecular mechanisms of antigenic variation and DNA repair in Trypanosoma brucei , the causative agent of Human African Trypanosomiasis. Her research integrates molecular, biochemical, and high-throughput approaches to study DNA recombination and immune evasion. Institut Pasteur, Paris (2016–Present) PhD, London School of Hygiene and Tropical Medicine Her research interests center on antigenic variation , DNA repair , and homologous recombination in trypanosomes. She investigates how DNA double-strand breaks influence variant surface glycoprotein (VSG) switching, a critical process for parasite survival in the host. Her lab uses advanced techniques such as RIT-seq, phosphoproteomics, and CRISPR-based tools to dissect these mechanisms at the molecular level. The recent publications of Lucy Glover span molecular parasitology, DNA damage response, and diagnostic development. Key themes include the role of the MRN complex in DNA repair, phosphoproteomic profiling of DNA damage responses, and the design of CRISPR-based diagnostics for HAT. Her work reveals how chromosomal context influences repair pathways and antigenic variation, contributing to a deeper understanding of parasite biology. While no formal scientific awards are listed in the provided text, her contributions are evident through high-impact publications and leadership in collaborative research projects. Lucy Glover advises several PhD and postdoctoral researchers, including Emilia MacLaughlin, Nuria Sima Teruel, and Alix Thivolle. Her lab is supported by institutional initiatives such as LabEx IBEID and transversal drug discovery programs. She collaborates with teams working on host-pathogen interactions, genomics, and infectious disease epidemiology. Her laboratory is part of the Department of Parasites and Insect Vectors and participates in departmental retreats and seminars. The team includes post-docs, research engineers, and administrative staff, reflecting a collaborative and interdisciplinary research environment focused on combating neglected tropical diseases.

• Molecular Parasitology
• DNA Repair
• Antigenic Variation
• +۷ مورد دیگر

Christopher Price is an Associate Professor at the Ammon Pinizzotto Biopharmaceutical Innovation Center, University of Delaware. His research focuses on musculoskeletal biomechanics, bone adaptation, and cartilage degeneration, with a particular emphasis on mechanotransduction and fluid flow dynamics in tissues. He holds a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine (2008) and a B.Sc. in Biomedical Engineering from Boston University (2000). Dr. Price’s research interests include the role of load-induced fluid flow in bone and cartilage health, advanced bioimaging techniques, and the development of disease-modifying therapies for osteoporosis and osteoarthritis. His work has received national/international recognition, including the Orthopaedics Research Society’s New Investigator Recognition Award (2010) and multiple Young Investigator Awards (2009–2010). Research focuses on mechanobiology, mechanosensory pathways, and tissue adaptation in musculoskeletal systems. Key areas: post-traumatic osteoarthritis, cartilage lubrication, and aging-related bone fragility. Utilizes cross-disciplinary methods: biomechanics, imaging, cell biology, and animal models. Publications span topics like solute transport in bone, cartilage tribology, and genetic influences on bone healing. His lab explores translational applications of mechanotransduction research to develop therapies targeting musculoskeletal diseases.

• Biomechanics
• Fluid Mechanics
• Musculoskeletal Biology
• +۶ مورد دیگر

Dr. J. Kent Werner is an Associate Professor in the Department of Neurology at the Uniformed Services University (USU) in Bethesda, MD, and serves as an active-duty Commander in the U.S. Navy Medical Corps. He holds adjunct faculty status at Johns Hopkins University School of Medicine and directs research at the Walter Reed Sleep Disorders Center. His expertise includes sleep medicine, neurology, and traumatic brain injury (TBI) management. Education: B.S. in Chemistry and Spanish from the United States Naval Academy (1997–2001) M.D. and Ph.D. in Neuroscience & Cellular/Molecular Medicine from Johns Hopkins University School of Medicine (2003–2012) Medicine Internship and Neurology Residency at Johns Hopkins SOM (2012–2016) Fellowship in Sleep Medicine at Walter Reed National Military Medical Center (WRNMMC) (2018–2019) Research focuses on TBI’s impact on sleep physiology, glymphatic system dynamics, and neurodegenerative biomarkers. He explores therapeutic strategies for TBI-related neurological disorders and sleep disturbances. His work integrates molecular, electrophysiological, and clinical approaches to understand brain injury mechanisms. Scientific Awards: American Academy of Sleep Medicine Annual Investigator Award (2020) First Place, Johns Hopkins Sleep and Circadian Research Day Poster Competition (2019) Joint Service Commendation Medal (2018) Johns Hopkins Neurology 'Brain Award' for Teaching (2014) Dr. Harold Lamport Medical Research Scholar Award (2006) Howard Hughes Medical Institute Research Fellowship Award (2005) Advising/Grants: While no formal advisees are listed, Dr. Werner has contributed to training through his teaching roles and clinical mentorship. His research has been supported by the Department of Veterans Affairs (HSR&D Mild TBI Diag. and Treatment) and the Combat Casualty Care Research Program (CENC). Labs/Teams: Directs research at the Walter Reed Sleep Disorders Center and collaborates with the National Intrepid Center of Excellence (NICoE) on TBI-related studies. Previously served as Chief of Neurology at Fort Belvoir Community Hospital.

• Sleep Physiology
• Traumatic Brain Injury (TBI)
• Neurodegeneration Biomarkers
• +۴ مورد دیگر

Vignesh Ramesh is a Research Assistant in Translational Biology at the Department of Biochemistry and Molecular Biology , University of Southern Denmark. His research focuses on metabolic pathways in cancer biology, particularly non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), with an emphasis on Epithelial-Mesenchymal Transition (EMT) and CRISPR/Cas9 applications. He has contributed to 15+ peer-reviewed publications and media-featured studies on metabolic inhibitors for cancer therapy.

• Cancer Biology
• Biochemistry
• Molecular Biology
• +۸ مورد دیگر

Carmine Settembre serves as an Associate Investigator at TIGEM (Telethon Institute of Genetics and Medicine) and holds the position of Full Professor of Histology in the Department of Clinical Medicine and Surgery at the University of Naples 'Federico II' in Italy. His research focuses on the lysosomal-autophagy pathway and its critical role in cellular homeostasis and human diseases. Dr. Settembre completed his pharmaceutical chemistry degree at the University of Naples 'Federico II' in 2002, followed by PhD studies at TIGEM. He then pursued postdoctoral research at Columbia University in New York and Baylor College of Medicine in Houston before returning to Italy in 2013 to establish his independent laboratory through the Dulbecco Telethon Institute career award program. He was appointed Associate Professor in Histology and Embryology at the University of Naples 'Federico II' in 2018. His research program investigates the mechanisms of selective autophagy, particularly ER-phagy, and lysosome biogenesis in response to cellular needs. The laboratory employs a multidisciplinary approach combining mouse genetics, cell biology, pharmacology, and gene editing with omics technologies to develop therapeutic strategies for diseases characterized by intracellular accumulation of toxic materials, including lysosomal storage disorders and conditions involving protein misfolding. Ian Boyle award from the European Calcified Tissue Society (ECTS) EMBO Young Investigator status ERC Starting Grant (BONEPHAGY, 2017-2023) ERC Proof of Concept Grant (RE-STORE, 2021-2022) ERC Consolidator Grant (AUTO-SELECT, 2023-2027) National Mucopolysaccharidosis Society funding (2021-2022) Dr. Settembre leads a research group comprising multiple postdoctoral fellows, a PhD student, a fellow, and technicians. His laboratory is part of the Cell Biology and Disease Mechanisms research unit at TIGEM, where they exploit institutional resources to address fundamental questions in the lysosome-autophagy pathway and develop novel therapies for genetic diseases.

• Cell Biology
• Autophagy
• Lysosomal Biology
• +۵ مورد دیگر

Blagoy Blagoev is a Professor at the University of Southern Denmark , Department of Biochemistry and Molecular Biology, and a leading researcher in Biomedical Mass Spectrometry and Systems Biology . He serves as Principal Investigator (PI) in the ATLAS Center for Functional Genomics and Tissue Plasticity , focusing on metabolic disorders and ubiquitin signaling. Department of Biochemistry and Molecular Biology ATLAS Center Research Interests : His work spans Proteomics , Ubiquitination , Metallic Dysfunction-Associated Steatotic Liver Disease , and Stem Cell Differentiation . Recent projects include investigating hepatic stellate cell metabolism and non-canonical ubiquitin signaling mechanisms . Scientific Trends : Recent publications highlight multi-omics approaches to liver disease, pharmacological targeting of CK2 in obesity, and fetal metabolic adaptation during maternal inflammation. The work integrates mass spectrometry , single-cell analysis , and signaling pathway mapping . Grants & Collaborations : Active in international collaborations, he participates in projects funded by the U.S. Department of Defense , Novo Nordisk Foundation , and Danish Research Council . Current grants explore PD-1 signaling , mesenchymal stem cell transcription complexes , and adipose-liver crosstalk . PhD Supervision : Mentors students including Christoffer Wernberg , Francesca Boel , and Ditte Hansen in proteomics and metabolic research.

• Proteomics
• Mass Spectrometry
• Ubiquitination
• +۵ مورد دیگر

Brage Storstein Andresen is a Professor in Translational Biology at the Department of Biochemistry and Molecular Biology, University of Southern Denmark. His research focuses on molecular genetics, RNA splicing mechanisms, and genetic diseases, particularly in the areas of metabolic disorders and enzyme deficiencies. His research interests center on understanding how genetic mutations affect RNA splicing and contribute to disease, with particular expertise in exon vulnerability, pseudoexon activation, and developing RNA-based therapies. His work bridges fundamental molecular biology with clinical applications, especially in newborn screening and metabolic disorders like propionic acidemia and medium-chain acyl-CoA dehydrogenase deficiency. Analysis of his recent publications reveals a strong focus on RNA splicing mechanisms, with increasing emphasis on therapeutic applications. His research combines molecular biology, biochemistry, and genetic engineering approaches, particularly CRISPR technology and splice-switching oligonucleotides, to develop treatments for genetic disorders. A significant portion of his work addresses metabolic diseases and cancer-related pathways involving protein kinase CK2. Active participant in multiple research projects through 2026 Editor of research journal Membership in scientific committees Professor Andresen has delivered numerous presentations on genetic splicing mechanisms and their disease implications, including the notable talk 'WHEN THE GENETIC CODE IS NOT ENOUGH: How single nucleotide changes can affect pre-mRNA splicing and cause disease.' His research has attracted significant media attention, with coverage in multiple news outlets and social media platforms.

• Molecular Genetics
• RNA Splicing
• Genetic Diseases
• +۷ مورد دیگر

Julien Roche is an Associate Professor in the Roy J. Carver Department of Biochemistry at Iowa State University. His research focuses on protein folding, dynamics, and evolution using high-pressure NMR spectroscopy and biophysical methods. He holds a B.S. and M.S. in Biology and Biophysics from the University of Montpellier, France, followed by a Ph.D. in Structural Biology and a postdoctoral fellowship at NIH/NIDDK under Dr. Ad Bax. Roche's work explores protein free-energy landscapes, intrinsically disordered proteins, amyloid peptides, and viral protein evolution. His lab employs NMR, X-ray crystallography, and molecular dynamics simulations to study proteins involved in neurodegenerative and infectious diseases. Key projects include HIV protease drug resistance mechanisms and the structural basis of transcription factor ATF4 regulation. His lab is funded by NIH NIGMS (R01GM132561) for studying DISC1 in cAMP pathways. Collaborators include Vincenzo Venditti (NMR methods), Baoyu Chen (actin signaling), and Alan DiSpirito (bacterial bioenergetics). The lab houses advanced NMR spectrometers (800/700 MHz), chromatography systems, and high-pressure NMR equipment. Roche's recent work highlights high-pressure NMR for detecting protein conformations, thermodynamic stability of low-complexity domains, and structural elucidation of enzyme I monomers. His findings bridge protein structure, dynamics, and disease mechanisms, advancing therapeutic strategies for neurodegenerative and viral diseases.

• Protein folding
• NMR spectroscopy
• Biophysical methods
• +۶ مورد دیگر

Dr. Lauren Gollahon is a Professor and Associate Chair in the Department of Biological Sciences at Texas Tech University. She holds a Ph.D. in Veterinary Anatomy from Texas A&M University (1990), an M.S. in Zoology (1986), and a B.A. in Marine Biology from Barrington College (1981). Her postdoctoral training includes work at MD Anderson Cancer Center (rat mammary carcinogenesis) and UT Southwestern Medical Center (breast cancer progression). Her research investigates obesity-cancer relationships, mitochondrial dysfunction in cancer, natural product therapeutics, and nutrition-based interventions. She collaborates across Nutritional Sciences, Animal Sciences, and Veterinary Sciences, integrating molecular pathways into a "One Health" framework. Research groups include: Biomedical Science Obesity Research Institute Texas Center for Comparative Cancer Research (TC3R) Recent publications (2022-2024) demonstrate a focus on: 1) Obesity-driven cancer mechanisms via adipocytokines and tumor microenvironments, 2) Natural compounds (e.g., chlorogenic acid, cinnamaldehyde) as anticancer agents, and 3) Dietary interventions (ammonium hydroxide-modified proteins, pH modulation) for metabolic health. Most studies employ murine models or in vitro systems with strong translational emphasis. Dr. Gollahon actively mentors graduate researchers. Her PhD students design hypothesis-driven projects (4-5 years), while MS students contribute to lab priorities (2-3 years). She prohibits AI in hypothesis generation or manuscript writing, emphasizing empirical creativity. Current lab infrastructure supports cellular, tissue, and tumor analysis.

• Cancer Biology
• Cancer Therapeutics
• Obesity and Cancer
• +۴ مورد دیگر

Dr. Chandrika Behura is an Associate Professor in the Department of Pediatrics, Division of Hematology and Oncology at Penn State College of Medicine. She is a board-certified hematologist/oncologist with a strong commitment to research in childhood cancer, particularly leukemia and neuroblastoma. Her work is supported by several extramural grants and she has established herself as a national leader in pediatric hematology/oncology research. Dr. Behura's research focuses on the role of Ikaros tumor suppressor and pro-oncogenic casein Kinase II (CK2) in leukemogenesis and drug resistance. Her most notable work, published in Blood in 2015, established a novel approach of using specific CK2 inhibitors for treatment of high-risk B cell lineage leukemia using PDX models. She has presented her work at various national and international scientific forums and gained national recognition as an outstanding young investigator. Analysis of Dr. Behura's publications reveals a consistent focus on molecular mechanisms of childhood leukemia, particularly the role of CK2 signaling pathways. Her research spans basic science investigations of gene regulation in hematopoietic cells to clinical applications of novel therapeutics. Recent work has expanded into cancer epidemiology and educational innovations for physician-scientist training. Distinguished Educator Award (2024) Outstanding Early-Stage Investigator Award (2018) Scholarship in Education Award (2022) Dr. Behura's research is currently supported by several extramural grants. She has also authored numerous chapters and review articles related to leukemia, CK2 and Ikaros. Her work contributes to UN Sustainable Development Goals related to good health and well-being. She is actively involved in the Penn State Cancer Institute and Penn State Neuroscience Institute, focusing on next-generation therapies for childhood cancers.

• Childhood cancer research
• Leukemia
• Neuroblastoma
• +۶ مورد دیگر

Tom Beneke is an independent Junior Research Group Leader at the Chair of Cell and Developmental Biology within the Biocenter at the University of Würzburg. His research focuses on Leishmania parasites, studying their pathogenic mechanisms and host interactions using advanced CRISPR-based genomic tools. He holds an EMBO Postdoctoral Fellowship and a Marie Curie Skłodowska Fellowship, and has secured funding from DFG and DRUID. Beneke's lab investigates how Leishmania species manipulate macrophage migration to control disease dissemination, employing high-throughput CRISPR screens and novel genetic methods like LeishBASEedit. Key research areas include drug resistance, tissue tropism, and functional genomics in parasitic protozoans. Education: PhD from University of Oxford (2015–2019), PostDoc at Sir William Dunn School of Pathology (2019–2020). Industry experience at OXGENE (2020–2022) included CRISPR screening for target discovery. Current lab members include PhD students, postdocs, and master's students working on CRISPR technologies and Leishmania pathogenesis. Scientific awards include EMBO Postdoctoral Fellowship (2021), Marie Curie Fellowship (2022), and grants from DFG (2023–present) and DRUID (2023–present). Over 20 peer-reviewed publications span CRISPR methodologies, Leishmania genetics, and parasite motility. The lab collaborates globally on projects like developing reference strains for gene editing and dissecting host-parasite interactions. Advising and grants: Supervises 5+ graduate students and manages funding from multiple agencies. Current projects include CRISPR base-editing screens and functional dissection of species-specific mechanisms in Leishmania. The lab also maintains a dynamic team of technicians and alumni contributors.

• Molecular Biology
• Parasitology
• CRISPR Gene Editing
• +۴ مورد دیگر

Dr. Alexandre Dubrac is an Adjunct Associate Professor in the Department of Pathology and Cell Biology at Université de Montréal and a researcher at the CHU Sainte-Justine Research Center. His research focuses on molecular mechanisms underlying vascular morphogenesis and disease, particularly in retinopathies and congenital vascular malformations. He holds a PhD in Angiogenesis from the University of Bordeaux (2008) and completed postdoctoral training at Yale University (2012-2018) and Paul Sabatier University (2009-2011). Education: PhD in Angiogenesis, INSERM U1029, University of Bordeaux (2005-2008) Master’s in Cellular, Molecular, and Developmental Biology, INSERM U589, Paul Sabatier University (2003-2004) Bachelor’s in Biology, Paul Sabatier University (2002) His lab investigates endothelial cell and pericyte interactions, TGFβ signaling in retinal vascular quiescence, and therapeutic targets for proliferative retinopathies. Key projects include studying TGFβ’s role in retinal EC proliferation and identifying pericyte markers to combat pathological angiogenesis. Research Highlights: Discovered Slit2/Robo1 signaling’s essential role in retinal vascularization Identified NCK-dependent pericyte migration in ischemic retinopathy Explored SMAD4’s inhibition of Casein Kinase 2 in vascular malformations Awards and Funding: Chercheur-boursier (junior 1), FRQS (2019-2023) IRSC Major Grant (2019-2024) American Heart Association Scientific Development Grant (2017-2020) Labs and Collaborations: Leads the Control of Organotypic Vascular Morphogenesis and Quiescence lab at CHU Sainte-Justine, collaborating with institutions like Yale University and INSERM.

• Vascular Biology
• Angiogenesis
• Retinopathy
• +۳ مورد دیگر

Dr. Chandrika G. Behura is an Associate Professor in the Department of Pediatrics, Division of Hematology and Oncology at Penn State University College of Medicine. She is affiliated with the Penn State Cancer Institute and Penn State Neuroscience Institute, focusing on Cancer Institute, Next-Generation Therapies. As a board-certified hematologist/oncologist, she maintains clinical expertise in pediatric hematology/oncology with specific services including anemia, bleeding and clotting disorders, experimental therapeutics, hemolytic disease in newborns, immune thrombocytopenia, platelet disorders, thrombotic autoimmune disorders, brain tumors, hematologic malignancies, hemophilia, pediatric bone marrow transplantation, and sickle cell disease. Dr. Behura's educational background includes: Medical School at Bangalore Medical College (2005) Residency in Pediatrics at Monmouth Medical Center (New Jersey) (2010) Fellowship in Pediatric Hematology/Oncology at Milton S. Hershey Medical Center (2013) Her research focuses on childhood cancer, particularly leukemia and neuroblastoma. Dr. Behura's major research project investigates the role of Ikaros tumor suppressor and pro-oncogenic casein Kinase II (CK2) in leukemogenesis and drug resistance. Her landmark 2015 publication in Blood established the novel approach of using specific CK2 inhibitors for treatment of high-risk B cell lineage leukemia using PDX models. She has presented her work at numerous national and international scientific forums and gained recognition as an outstanding young investigator. Her research is currently supported by several extramural grants, and she has authored multiple chapters and review articles related to leukemia, CK2, and Ikaros. Additional projects focus on designing novel therapeutic strategies for high-risk neuroblastoma, the most common abdominal solid tumor in young children with poor prognosis. Her publication record shows consistent scholarly output with 21 research outputs between 2013-2024, including articles, review articles, letters, and book chapters. The research demonstrates a clear trajectory from foundational molecular work on CK2 and Ikaros to clinical applications and broader cancer epidemiology studies. Dr. Behura has received significant recognition for her work: Distinguished Educator Award (2024) Outstanding Early-Stage Investigator Award (2018) Scholarship in Education Award (2022) Her research is supported by multiple extramural grants, and she actively participates in the Clinician-Scientist Faculty Mentoring Program (FAME), which she co-developed to increase scholarly productivity and grant funding at Penn State. Dr. Behura collaborates extensively within Penn State's Cancer Institute and Neuroscience Institute, contributing to next-generation therapies research. Her work aligns with UN Sustainable Development Goals related to health and well-being, particularly in advancing treatments for childhood cancers.

• Pediatric Hematology/Oncology
• Leukemia Research
• Neuroblastoma
• +۵ مورد دیگر